Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | LIPC | P11150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2439748 | 0.90 | USP30 (0.47) | USP30RORCGPR119 | |
| SCHEMBL2434897 | 0.84 | USP30 (0.38) | USP30RORCGPR119MEN1KMT2A | |
| SCHEMBL2059484 | 0.81 | HSD11B1 (0.40) | USP30GRIN2BEPHX2 | |
| SCHEMBL18321103 | 0.78 | NR1H2 (0.36) | RORCGPR119EPHX2 | |
| SCHEMBL2146337 | 0.78 | NR1H2 (0.36) | RORCGPR119EPHX2 | |
| SCHEMBL23942085 | 0.78 | NR1H2 (0.36) | RORCGPR119EPHX2 | |
| SCHEMBL16434828 | 0.76 | USP30 (0.52) | HDAC1HDAC2LIPGUSP30RORC | |
| SCHEMBL1260709 | 0.76 | HSD11B1 (0.35) | USP30RORCGPR119 | |
| SCHEMBL3305629 | 0.75 | ADRB2 (0.35) | RORCGPR119MEN1KMT2A | |
| SCHEMBL704571 | 0.75 | ABCB1 (0.41) | USP30RORCGPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | HDAC1 81/4885HDAC2 191/4885LIPG 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.